Company: OCEA
Filing Date: 2025-04-08
Form Type: 10-K
Source: 0001641172-25-003155
Chunk: 1605

Company: Ocean Biomedical, Inc.
Filing Date: 2025-04-08
Form: 10-K
Item: Item 11
Chunk 1605
---
     (1,469) 
     1,171 
  
    Loss in connection with the Share Consideration shares 
     -  
     (12,676)
  
    Loss in connection with Backstop Put Option Liability and Fixed Maturity Consideration 
     (1,983) 
     (62,646)
  
    Fair value of warrant issuances 
     -  
     (2,301)
  
    Fair value of non-cash stock issuances 
     -  
     (740)
  
    Transaction costs 
     (356) 
     (8,732)
  
    Loss on extinguishment of debt 
     -  
     (15,080)
  
    Loss on exchange of notes 
     (85) 
     - 
  
    Interest expense, including amortization of debt issuance costs 
     (2,046) 
     (1,762)
  
    Net loss attributable to equity interest in Virion 
     (3,301) 
     (708)
  
    Change in fair value of Virion Contribution Liability 
     3,605  
     (777)
  
    Fair value of stock obligations 
     (47) 
     - 
  
    Other 
     -  
     (1)
  
    Total other income (expense) 
     (5,682) 
     (104,252)
  
    NET LOSS 
    $(9,480) 
    $(114,466)

    Weighted average shares outstanding, basic and diluted 
     27,502,537  
     26,292,438 
  
    Net loss per share, basic and diluted 
    $(0.34) 
    $(4.35)

See
accompanying notes to the consolidated financial statements

F-5

OCEAN
BIOMEDICAL, INC. AND SUBSIDIARIES

CONSOLIDATED
STATEMENTS OF STOCKHOLDERS’ DEFICIT

FOR THE FISCAL YEARS ENDED DECEMBER 31, 2024 AND 2023

(in
thousands)

    Shares  
    Amount  
    Capital  
    Deficit  
    Deficit 

    Common  
    Additional Paid-In  
    Accumulated  
    Total Stockholders’ 

    Shares  
    Amount  
    Capital  
    Deficit